Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
Antibiotics · 26.07.2023 · 12 (8) · 1233
DOI: 10.3390/antibiotics12081233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 26.07.2023. Verfasst von Giovanni Boscarino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Neonatal sepsis is a bacterial bloodstream infection leading to severe clinical manifestations frequently associated with death or irreversible long-term deficits. Antibiotics are the drug of choice to treat sepsis, regardless of age. In neonates, the lack of reliable criteria for a definite diagnosis and the supposition that an early antibiotic administration could reduce sepsis development in children at risk have led to a relevant antibiotic overuse for both prevention and therapy. The availability of biomarkers of neonatal sepsis that could alert the physician to an early diagnosis of neonatal sepsis could improve the short and long-term outcomes of true sepsis cases and reduce the indiscriminate and deleterious use of preventive antibiotics. The main aim of this narrative review is to summarize the main results in this regard and to detail the accuracy of currently used biomarkers for the early diagnosis of neonatal sepsis. Literature analysis showed that, despite intense research, the diagnosis of neonatal sepsis and the conduct of antibiotic therapy cannot be at present decided on the basis of a single biomarker. Given the importance of the problem and the need to reduce the abuse of antibiotics, further studies are urgently required. However, instead of looking for new biomarkers, it seems easier and more productive to test combinations of two or more of the presently available biomarkers. Moreover, studies based on omics technologies should be strongly boosted. However, while waiting for new information, the use of the clinical scores prepared by some scientific institutions could be suggested. Based on maternal risk factors and infant clinical indicators, sepsis risk can be calculated, and a significant reduction in antibiotic consumption can be obtained.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
- Neonatal Unit, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
- Università degli Studi di Milano, 20122 Milan, Italy.
ORCID-Profile: Giovanni Boscarino, Serafina Perrone, Nicola Principi
Zitieren
APA
Boscarino, G., Migliorino, R., Carbone, G., Davino, G., Dell'Orto, V. G., Perrone, S., Principi, N., & Esposito, S. (2023). Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going. Antibiotics, 12(8), 1233. https://doi.org/10.3390/antibiotics12081233
Vancouver
Boscarino G, Migliorino R, Carbone G, Davino G, Dell'Orto VG, Perrone S, et al. Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going. Antibiotics. 2023;12(8):1233. doi:10.3390/antibiotics12081233
BibTeX
@article{Boscarino2023,
author = {Boscarino, Giovanni and Migliorino, Rossana and Carbone, Giulia and Davino, Giusy and Dell'Orto, Valentina Giovanna and Perrone, Serafina and Principi, Nicola and Esposito, Susanna},
title = {Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {8},
pages = {1233},
doi = {10.3390/antibiotics12081233}
}
EUVIMED